PCR93 Effect of Physicians’ Prescribing Choices of First- or Second-Line Tumor Necrosis Factor Inhibitor Biologics Versus Non-Tumor Necrosis Factor Inhibitor Biologic Therapies on Psoriatic Arthritis Patient-Reported Outcomes

Rahul Patel(Icahn School of Medicine at Mount Sinai), Oluwakayode Adejoro(Janssen (United States)), Ernesto Quiñones(Adelphi Group (United Kingdom)), Chenglong Han(Janssen (United States)), Martin P. Edwards(Pfizer (United States)), N. Massey(Adelphi Group (United Kingdom)), Megan Hughes(Adelphi Group (United Kingdom))
Value in Health
June 1, 2023
10.1016/j.jval.2023.03.1871
Cited by 0

Related Papers

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
|Journal of Medicinal Chemistry|2014|587
Using the Golden Triangle to optimize clearance and oral absorption
|Bioorganic & Medicinal Chemistry Letters|2009|382
Lipophilic Efficiency as an Important Metric in Drug Design
|Journal of Medicinal Chemistry|2018|340
Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis
|Bioorganic & Medicinal Chemistry Letters|2009|269